1. Home
  2. SLN vs ACDC Comparison

SLN vs ACDC Comparison

Compare SLN & ACDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

N/A

Current Price

$19.78

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo ProFrac Holding Corp.

ACDC

ProFrac Holding Corp.

N/A

Current Price

$3.51

Market Cap

1.1B

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
SLN
ACDC
Founded
1994
2014
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oilfield Services/Equipment
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
SLN
ACDC
Price
$19.78
$3.51
Analyst Decision
Hold
Sell
Analyst Count
5
4
Target Price
★ $19.75
$5.16
AVG Volume (30 Days)
★ 4.3M
1.6M
Earning Date
11-24-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
$559,000.00
★ $1,941,800,000.00
Revenue This Year
N/A
$1.38
Revenue Next Year
$131.31
$17.80
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.19
$2.61
52 Week High
$19.87
$8.22

Technical Indicators

Market Signals
Indicator
SLN
ACDC
Relative Strength Index (RSI) 78.28 41.59
Support Level $13.01 N/A
Resistance Level $19.87 $5.41
Average True Range (ATR) 0.07 0.47
MACD -0.10 -0.11
Stochastic Oscillator 60.42 36.95

Price Performance

Historical Comparison
SLN
ACDC

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About ACDC ProFrac Holding Corp.

ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.

Share on Social Networks: